Multiple Myeloma: Targeting BCMA in the Heavily Pretreated Population

October 9, 2020

The rationale for using BCMA-targeted novel approaches such as antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies as treatment for patients with heavily pretreated relapsed/refractory multiple myeloma.